Alexa N. Fiffick, DO, MBS, MSCP

Articles by Alexa N. Fiffick, DO, MBS, MSCP

Panelists discuss the importance of addressing sleep disturbances in menopause management, even in the absence of vasomotor symptoms (VMS), and explore how emerging research on elinzanetant could impact sleep quality and its links to mood disorders, cardiovascular disease, and Alzheimer disease, while also contemplating the potential shift in the treatment paradigm for VMS with the introduction of new neurokinin-targeted therapies as either standard of care or in combination with other treatments.

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) compared with other treatments, as well as its impact on quality of life and the speed at which patients experienced symptom improvement.

Panelists discuss the role of neurokinin in the pathophysiology of vasomotor symptoms (VMS) and examine the mechanisms of action of novel nonhormonal agents such as fezolinetant and elinzanetant, highlighting the advantages of targeting neurokinin pathways over traditional hormonal treatments and their potential to address related menopause issues such as mood disturbances and sleep disorders.

Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.

Latest Updated Articles



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo